Uppsala Universitet - Akademiska Sjukhuset

Uppsala 75185

1 studies enrolling now · 4 studies all time

What they study most

Advanced Solid Tumors, Anal Carcinoma, Antibody-mediated Rejection, Basal Cell Carcinoma (Unresectable or Metastatic), Cervical Cancer, Clear Cell Ovarian or Endometrial Carcinoma, Cutaneous Squamous Cell Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L), End Stage Kidney Disease, Esophageal Squamous Cell Carcinoma, Follicular Lymphoma

Studies at this site

• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors — Stopped early
• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients — Stopped early